Sanofi Streamlines Pipeline Focus While Looking Ahead to a Post-COVID-19 World

Despite the bleak challenges brought on by COVID-19, Bill Sibold, executive vice president of Sanofi Genzyme, is optimistic that some of the greatest discoveries in medicine and treating various diseases are within the grasp of the pharmaceutical industry.

One day after Sanofi held its virtual Research and Development Day, Sibold spoke to BioSpace about the company’s core pipeline focus, programs aimed at COVID-19 and what the future of the industry and patient care could look like in a post-COVID-19 world.